Home » Stocks » MGTA

Magenta Therapeutics, Inc. (MGTA)

Stock Price: $8.21 USD -0.08 (-0.97%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 396.58M
Revenue (ttm) n/a
Net Income (ttm) -80.01M
Shares Out 48.26M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $8.21
Previous Close $8.29
Change ($) -0.08
Change (%) -0.97%
Day's Open 8.18
Day's Range 8.10 - 8.40
Day's Volume 151,568
52-Week Range 6.03 - 14.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood system...

Business Wire - 2 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more pa...

24/7 Wall Street - 1 month ago

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, CTMX, KLDO
Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility o...

Other stocks mentioned: BLUE
Zacks Investment Research - 1 month ago

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Other stocks mentioned: APRN, CACC, CLH, LOGC
Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more pa...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more pa...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to...

24/7 Wall Street - 3 months ago

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: ADT, FTI, FLY, NEX
Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more pa...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more pa...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more pa...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more pa...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more pa...

24/7 Wall Street - 6 months ago

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, CTMX, KLDO
Zacks Investment Research - 6 months ago

Magenta (MGTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transpl...

The Motley Fool - 6 months ago

The company announced the pricing of a public offering of common stock.

Business Wire - 7 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transpl...

PRNewsWire - 7 months ago

NEW YORK, June 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such investors a...

Business Wire - 7 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transpl...

PRNewsWire - 7 months ago

NEW YORK, June 15, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ("Mag...

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Magenta Therapeutics.

24/7 Wall Street - 1 year ago

The American Society of Hematology (ASH) hosted its 61st annual meeting, and one of the biggest biotech events, earlier this week in Orlando, Florida.

Other stocks mentioned: ARGX, BLUE, BPMC, EPZM, FATE
The Motley Fool - 1 year ago

New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.

Other stocks mentioned: MTEM
Zacks Investment Research - 1 year ago

Magenta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 1 year ago

Shares have risen by around 25% since my initial article.

The Motley Fool - 1 year ago

Can you guess what these high-flying stocks have in common?

Other stocks mentioned: AXSM, PHAS

About MGTA

Magenta Therapeutics, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansi... [Read more...]

Industry
Biotechnology
Founded
2015
CEO
Jason Gardner
Employees
70
Stock Exchange
NASDAQ
Ticker Symbol
MGTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for MGTA stock is "Strong Buy." The 12-month stock price forecast is 16.50, which is an increase of 100.97% from the latest price.

Price Target
$16.50
(100.97% upside)
Analyst Consensus: Strong Buy